Tirzepatide Research Reference — 10 mg

Tirzepatide (LY3298176) is a 39-residue modified peptide studied as an agonist of glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR). Published work has characterized receptor signaling, receptor internalization and downstream metabolic endpoints in non-clinical models.

In human receptor-expressing HEK293 systems, reported cAMP EC50 values were 6.54 nM at GLP-1R and 1.01 nM at GIPR; receptor internalization was also evaluated at 100 nM. These literature values are assay specific and are not release criteria for the supplied material.

Hallazgos publicados seleccionados

• Induced cAMP signaling in HEK293 cells expressing human GLP-1R or GIPR.
• Induced internalization of GLP-1R and GIPR in receptor-expressing cellular systems.
• Was evaluated in mouse models for metabolic and airway-response endpoints.

Interpretación de la literatura: This summary describes published experimental literature and is not a lot specification, clinical claim, use instruction or representation that the supplied research material will reproduce a published result. This record intentionally excludes dosing, administration, clinical outcomes, patient eligibility and therapeutic comparisons.